Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6194 (PT101) in Active Ulcerative Colitis
NCT04924114Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 1, randomised, double-blind trial of PT101 in ulcerative colitis (UC) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event at 85 days and Number of Participants Who Interrupted or Discontinued Study Treatment Due to an AE at 72 days. Started Oct 2021; status: completed.
02
Drugs
PT101
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04924114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924114.